MRK Price Prediction Next Week
Technical Analysis
Based on recent price action and technical indicators, MRK shows a bearish trend in the short term. The stock has been trading below its key moving averages, with significant resistance around $94 level. The recent Q4 earnings beat expectations, but weak 2025 guidance has created selling pressure.
News Impact
- MRK reported Q4 revenue of $15.6B (+7% YoY) and adjusted EPS of $1.72, beating estimates
- The company paused Gardasil shipments to China through at least mid-2025, affecting near-term revenue outlook
- MRK is relatively immune to potential trade tariff impacts, which is positive for the stock
- Wall Street maintains overall bullish stance with mean price target of $125.95 (26.2% upside)
Price Projection for Next Week Based on technical analysis and recent news:
- Resistance: $94.00
- Support: $90.00
- Target Range: $89.50 - $92.50
The stock is likely to remain under pressure due to:
- Weak guidance affecting investor sentiment
- Gardasil challenges in China
- Overall market uncertainty around healthcare sector
Trading Recommendation: SELL
- Entry: Current levels around $90-91
- Stop Loss: $94.50
- Target: $89.50
- Time Frame: 1 week
- Key Catalyst: Further news on China shipments and guidance updates
The stock shows bearish momentum with RSI indicating oversold conditions. Multiple analysts including Wells Fargo have maintained Hold ratings, suggesting limited upside in the immediate term.
MRK Similar Chart Price Prediction
The price of MRK is predicted to go up 39.01%, based on the high correlation periods with INFU. The similarity of these two price pattern on the periods is 97.43%.
MRK
INFU
Up: 39.01%Similarity: 97.43%
MRK Revenue Forecast
MRK EPS Forecast
MRK FAQs
What is MRK revenue forecast for next quarter？
What is MRK eps forecast for next quarter？
MRK VS S&P500
Keytruda looks best positioned in the immuno-oncology landscape, buoyed by a first-mover advantage in the important indication of first-line non-small cell lung cancer.
The growth in Merck's high margin cancer drugs should help expand the company's overall operating margin.
Merck supports a strong dividend yield that looks secure based on a wide diversified portfolio of drugs.
MRK Analyst's Forecast
Vamil Divan
Guggenheim
Strong Buy
2025-02-12
Price Target
$122 → $115
Upside
+38.07%
Guggenheim analyst Vamil Divan lowered the firm's price target on Merck to $115 from $122 and keeps a Buy rating on the shares. The firm is updating its company model following Q4 earnings and the company's initial FY25 guidance, noting that its lower target is mainly driven by lower sales estimates for Gardasil, partially offset by higher expectations on management's ability to execute on converting patients to subcutaneous Keytruda.
Terence Flynn
Morgan Stanley
Hold
2025-02-05
Price Target
$113 → $106
Upside
+18.21%
Terence Flynn
Morgan Stanley
Hold
2025-01-21
Price Target
$123 → $113
Upside
+17.41%
